Pharmaceutical Product Development, Inc. (NASDAQ:PPDI.DL)

CAPS Rating: No stars

The Company is a global contract research organization providing drug discovery and development services, post-approval expertise and compound partnering programs.

Recs

5
Player Avatar A6EIntruder (69.64) Submitted: 6/2/2009 10:52:25 AM : Outperform Start Price: $18.74 PPDI.DL Score: +44.22

Once upon a time I worked for a CRO called Quintiles, which has since gone back to being a private company--and remains the biggest CRO in the field today.

I was on their contract sales side, so I can't claim any clinical experience. However, even at the time (this is over a decade ago), I believed that the proposition for future CRO growth and success was a no-brainer. Drug companies get what they want, the CRO gets its share of the pie. I believe it is insulated to a greater degree than the big pharma which pays its bills from the shocks of healthcare reform ballyhoo since the bulk of their business is research.

Being a MF SA pick doesn't hurt either.

Featured Broker Partners


Advertisement